Management decisions in chronic myeloid leukemia

Seminars in Hematology ◽

10.1053/shem.2003.50009 ◽

2003 ◽

Vol 40 (1) ◽

pp. 97-103 ◽

Author(s):

John M. Goldman ◽

David Marin

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Management Decisions

Download Full-text

Management decisions in chronic myeloid leukemia

Seminars in Hematology ◽

10.1016/s0037-1963(03)70047-x ◽

2003 ◽

Vol 40 (1) ◽

pp. 97-103 ◽

Author(s):

John M. Goldman ◽

David Marin

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Management Decisions

Download Full-text

Uncommon long-term survival in a patient with chronic myeloid leukemia

Acta Oncologica ◽

10.1080/02841860903156475 ◽

2009 ◽

pp. 1-2

Author(s):

Fabio Stagno ◽

Paolo Vigneri ◽

Vittorio Del Fabro ◽

Stefania Stella ◽

Salvatore Berretta ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Term Survival ◽

Long Term Survival

Download Full-text

Decision letter for "Chronic myeloid leukemia‐derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells"

10.1002/eji.201848051/v4/decision1 ◽

2019 ◽

Keyword(s):

T Cells ◽

Chronic Myeloid Leukemia ◽

Regulatory T Cells ◽

Extracellular Vesicles ◽

Myeloid Leukemia ◽

Suppressive Activity

Download Full-text

Review for "Chronic myeloid leukemia‐derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells"

10.1002/eji.201848051/v1/review2 ◽

2019 ◽

Keyword(s):

T Cells ◽

Chronic Myeloid Leukemia ◽

Regulatory T Cells ◽

Extracellular Vesicles ◽

Myeloid Leukemia ◽

Suppressive Activity

Download Full-text

Decision letter for "Chronic myeloid leukemia‐derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells"

10.1002/eji.201848051/v1/decision1 ◽

2019 ◽

Keyword(s):

T Cells ◽

Chronic Myeloid Leukemia ◽

Regulatory T Cells ◽

Extracellular Vesicles ◽

Myeloid Leukemia ◽

Suppressive Activity

Download Full-text

Review for "Favourable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib"

10.1002/hon.2765/v2/review1 ◽

2020 ◽

Author(s):

Mark Heaney

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Favourable Outcome

Download Full-text

Decision letter for "Favourable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib"

10.1002/hon.2765/v2/decision1 ◽

2020 ◽

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Favourable Outcome

Download Full-text

Review for "Favourable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib"

10.1002/hon.2765/v1/review3 ◽

2020 ◽

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Favourable Outcome

Download Full-text

Decision letter for "A Phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha 2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia not achieving a deep molecular response (MR 4.5) – AGMT_CML 1"

10.1002/hon.2786/v2/decision1 ◽

2020 ◽

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

Chronic Phase ◽

Molecular Response ◽

Imatinib Treatment ◽

Phase 1 Study ◽

Deep Molecular Response

Download Full-text

Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia

Seminars in Hematology ◽

10.1053/shem.2001.27079 ◽

2001 ◽

Vol 38 (3, Suppl 8) ◽

pp. 9-14 ◽

Author(s):

Brian Druker

Keyword(s):

Signal Transduction ◽

Clinical Trials ◽

Chronic Myeloid Leukemia ◽

Phase I ◽

Myeloid Leukemia ◽

Phase I Clinical Trials

Download Full-text